Health Care & Life Sciences » Pharmaceuticals | Reata Pharmaceuticals Inc.

Reata Pharmaceuticals Inc. Cl A | Ownership

Companies that own Reata Pharmaceuticals Inc. Cl A

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
CPMG, Inc.
2,912,523
12.27%
-1,692,857
50.72%
07/27/2018
BlackRock Fund Advisors
1,153,952
4.86%
270,751
0.01%
06/30/2018
The Vanguard Group, Inc.
646,404
2.72%
44,080
0%
06/30/2018
Deerfield Management Company LP
609,554
2.57%
219,554
1.5%
06/30/2018
Emerald Advisers, Inc.
545,520
2.29%
51,767
1.62%
06/30/2018
Emerald Mutual Fund Advisers Trust
486,741
2.04%
15,627
1.41%
06/30/2018
Fidelity Management & Research Co.
468,990
1.98%
-160,861
0%
06/30/2018
Cormorant Asset Management LP
450,000
1.9%
0
2.74%
06/30/2018
Tavistock Life Sciences Co. (Investment Management)
325,000
1.37%
0
1.93%
06/30/2018
Kennedy Capital Management, Inc.
322,801
1.36%
84,491
0.5%
06/30/2018

About Reata Pharmaceuticals

View Profile
Address
2801 Gateway Drive
Irving Texas 75063
United States
Employees -
Website http://www.reatapharma.com
Updated 07/08/2019
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its lead product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.